The firm enrolled the first patient at Florida's BayCare Morton Plant Hospital, and the study procedure went according to protocol, per an investigator.

The firm is expecting Phase III readouts this year for its FGFR2b drug bemarituzumab and is advancing a second KRAS inhibitor to the clinic.

Researchers at AACR discussed what's next for the drug class, given the disappointing activity of tiragolumab with Tecentriq ...

DCx will gain rights to technology, targets, and preclinical programs from Repare along with lab space and staff in Montreal.

The companies will analyze RNA sequencing data from Scipher to identify biomarkers for patient stratification and drug development.

The company said it took financial hits from the Inflation Reduction Act's Medicare Part D redesign, which included higher ...

NEW YORK – Darmstadt, Germany-based Merck KGaA on Monday said it will buy SpringWorks Therapeutics, a company developing precision treatments for rare tumors, in a deal with an enterprise value of ...

Most adults in the US would take a blood test to assess whether they will develop Alzheimer's, according to the survey, ...

When patients with solid tumors had the same liquid- and tissue-based test findings, patients had better outcomes on molecular tumor board-guided therapy.

The clinical trial will include nearly 150 patients with advanced hepatocellular carcinoma that expresses glypican-3.

The cost savings will allow the firm to hire new employees who can support clinical trials of its DMD candidates and advance other therapeutic programs.

NEW YORK – Revolution Medicines' zoldonrasib, a drug targeting the KRAS G12D mutation in patients with non-small cell lung cancer, shrunk tumors in around 60 percent of patients in a clinical trial.